Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Emerging options for patients with DLBCL who relapse after CAR-T therapy

Emmanuel Bachy • 11 Jun 2022
EHA 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T

Emmanuel Bachy, MD, PhD, Lyon Sud Hospital Center, Lyon, France, comments on emerging treatment options for patients with diffuse large B-cell lymphoma (DLBCL) who relapse after CAR-T therapy, mentioning bispecific antibodies and allogeneic CAR-Ts. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Emmanuel Bachy

1:15
Emerging CAR-T therapies for T-cell lymphoma
Emmanuel Bachy • 11 Jun 2022
1:15
Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms
Emmanuel Bachy • 11 Jun 2022
1:45
Matched comparison of tisa-cel and axi-cel in R/R DLBCL
Emmanuel Bachy • 11 Jun 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals